Spotlight On... J&J signs pledge to combat antimicrobial resistance at Davos summit; Mindray vote set on take-private proposal; Philips rolls out Lifeline with fall detection; and more...

Johnson & Johnson ($JNJ) is one of more than 80 companies and organizations to sign the Declaration on Combating Antimicrobial Resistance, which was launched at the annual gathering of global bigwigs in Davos, Switzerland. "We are pleased to be part of this important initiative to combat antimicrobial resistance," Dr. Paul Stoffels, chief scientific officer and worldwide chairman of the company's pharmaceuticals unit, said in a statement. "Antimicrobials are the backbone of modern medicine, and have played a key role in increasing life expectancy globally. At Johnson & Johnson, our long-standing commitment to innovation in antimicrobial R&D is evident through our legacy products and our new efforts to support ongoing research. For the world to continue to have new antibiotics, we need investments in basic science and novel incentive models for industry R&D, and to protect our existing treatments, we need new frameworks for appropriate use." J&J used to sell Vitros immunodiagnostic systems to diagnose infectious diseases, but in 2014 sold the Ortho-Clinical Diagnostics division for $4 billion to the Carlyle Group. More

@FierceMedDev: IBM bets its future on machine learning and Watson Health. Article | Follow @FierceMedDev

@EmilyWFierce: Drug and diagnostic cos are teaming up to develop new antibiotics for superbugs. More from the WSJ (sub. req.) | Follow @EmilyWFierce

> Mindray ($MR) is holding a Feb. 26 shareholder meeting to vote on its take-private proposal. More

> Royal Philips ($PHG) announced its Lifeline GoSafe mobile medical alert service; it adds AutoAlert fall detection technology to the Lifeline emergency alert system. It's available in Canada. More

> A study of electroCore's handheld nVNS device found that use of it twice daily to stimulate the vagus nerves was effective in reducing the number of headache days per month and the monthly migraine attacks. More

Biotech News

@FierceBiotech: ICYMI: Abingworth tees up a unique, $105M co-development fund for PhIII deals. Article | Follow @FierceBiotech

@JohnCFierce: J&J halts a depression program in the shadow of a fatal French trial. News | Follow @JohnCFierce

@DamianFierce: the FDA is handling its breakup with $SRPT very childishly. just be honest and direct and maybe you can stay friends. | Follow @DamianFierce

> GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme. Report

> FDA snow day delays review of Sarepta's Duchenne drug. Item

> Alkermes slammed as top depression drug fails two PhIIIs. Article

Pharma News

@FiercePharma: Vaccines present 'biggest breakthrough' in animal health: Report. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Poland says Mylan halted production at Agila Specialties plant after inspectors found issues. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. FiercePharma article | Follow @CarlyHFierce

> Glaxo CEO: Consumer health can stand on its own, but don't expect a quick spinoff. Story

> U.K. competition watchdog targets pharma for 'substantial fines.' Article

CRO News

> Parexel moves to buy a pharma consulting firm. News

> Catalent extends its clinical supply biz into Japan. More

> BioClinica buys into cost management with its latest deal. Report

> Biosimilars developer Celltrion taps Medidata for trial tech. Story

> French CRO Biotrial tries to move forward after disastrous clinical study. Article

Pharma Manufacturing News

> China ingredient maker's plant found in 'devastated state' by authorities. News

> Catalent expanding Japanese manufacturing site to offer clinical services. Item

> FDA says microbial contamination found at Montana Compounding. Report

> FDA bans products from another Chinese plant. Story

> Pfizer reportedly striking deal with Polysan for Russian production. Article

Pharma Asia News

> Japan's Daiichi Sankyo, Coherus become players in Enbrel biosimilar race. More

> China FDA plowed through trial and new drug applications in 2015, commissioner says. Report

> Japan's Chiyoda plans on big growth in drug plant building. Story

> AstraZeneca survives Onglyza compulsory license challenge in India. Article

> Medical reps in India face the boot from doctors' offices. Report

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.